Hypnotic Intake and Motor and Cognitive Performances at High Altitude
- Registration Number
- NCT02778659
- Lead Sponsor
- Centre d'Expertise sur l'Altitude EXALT
- Brief Summary
This study aims to determine the effect of acute hypnotic intake (Zolpidem) on sleep, cognitive and motor performances and on acute mountain sickness symptoms at high altitude. Healthy subjects will be evaluated on 4 occasions (twice at sea level and twice at high altitude), after hypnotic or placebo intake. Following an early wake-up (01:00), symptoms, cognitive and motor performances will be assessed to determine potential residual effects of Zolpidem within such conditions.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
- No sojourn above 2500 m during the past 2 months
- Coffee intake < 3 cups per day
- Non-smoker
Exclusion Criteria
- Respiratory, cardiovascular, metabolic or neuromuscular diseases
- Psychiatric disorders
- Use of hypnotics within the past year
- Dependence syndrome (alcool, drugs, etc)
- Severe insomnia or somnolence
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Placebo Normoxia Placebo Acute placebo intake at sea level Placebo Hypoxia Placebo Acute placebo intake at high altitude Zolpidem Normoxia Zolpidem Acute zolpidem intake at sea level Zolpidem Hypoxia Zolpidem Acute zolpidem intake at high altitude
- Primary Outcome Measures
Name Time Method Cognitive performance assessed using Simon cognitive test 4 hours after drug/placebo intake Simon cognitive test
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Grenoble University Hospital
🇫🇷Grenoble, Rhone Alpes, France